KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Leases (2018 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Operating Leases for 7 consecutive years, with $288.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 2.7% year-over-year to $288.0 million, compared with a TTM value of $288.0 million through Dec 2025, down 2.7%, and an annual FY2025 reading of $288.0 million, down 2.7% over the prior year.
  • Operating Leases was $288.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from $283.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $525.0 million in Q4 2021 and bottomed at $281.0 million in Q2 2024.
  • Average Operating Leases over 5 years is $352.2 million, with a median of $331.0 million recorded in 2023.
  • The sharpest move saw Operating Leases skyrocketed 543.94% in 2021, then dropped 27.6% in 2023.
  • Year by year, Operating Leases stood at $525.0 million in 2021, then fell by 15.81% to $442.0 million in 2022, then decreased by 27.6% to $320.0 million in 2023, then dropped by 7.5% to $296.0 million in 2024, then fell by 2.7% to $288.0 million in 2025.
  • Business Quant data shows Operating Leases for TEVA at $288.0 million in Q4 2025, $283.0 million in Q3 2025, and $296.0 million in Q2 2025.